Regulation of bcl-2 expression by Ubc9

Experimental Cell Research

Volumn 312, Issue 10, 2006, Pages 1865-1875

  Lu, Zhaohui ^a   Wu, Hailong ^a   Mo, Yin Yuan ^a  

^a SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

bcl 2; SRC 1; SUMO; Sumoylation; Ubc9

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; ESTRADIOL; ESTROGEN RECEPTOR; LUCIFERASE; PROTEIN BCL 2; PROTEIN UBC9; RALOXIFENE; STEROID RECEPTOR; STEROID RECEPTOR COACTIVATOR 1;

ARTICLE; CARCINOGENESIS; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; ESTROGEN RESPONSIVE ELEMENT; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; REPORTER GENE; WILD TYPE;

EID: 33646938710     PISSN: 00144827     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yexcr.2006.02.017     Document Type: Article

References (52)

1. Muller S., Hoege C., Pyrowolakis G., and Jentsch S. SUMO, ubiquitin's mysterious cousin. Nat. Rev. Mol. Cell Biol. 2 (2001) 202-210
2. Johnson E.S. Protein modification by SUMO. Annu. Rev. Biochem. 73 (2004) 355-382
3. Hershko A., and Ciechanover A. The ubiquitin system. Annu. Rev. Biochem. 67 (1998) 425-479
4. Johnson E.S., Schwienhorst I., Dohmen R.J., and Blobel G. The ubiquitin-like protein Smt3p is activated for conjugation to other proteins by an Aos1p/Uba2p heterodimer. EMBO J. 16 (1997) 5509-5519
5. Tatham M.H., Kim S., Jaffray E., Song J., Chen Y., and Hay R.T. Unique binding interactions among Ubc9, SUMO and RanBP2 reveal a mechanism for SUMO paralog selection. Nat. Struct. Mol. Biol. 12 (2005) 67-74
6. Yasugi T., and Howley P.M. Identification of the structural and functional human homolog of the yeast ubiquitin conjugating enzyme UBC9. Nucleic Acids Res. 24 (1996) 2005-2010
7. Wang Z.Y., Qiu Q.Q., Seufert W., Taguchi T., Testa J.R., Whitmore S.A., Callen D.F., Welsh D., Shenk T., and Deuel T.F. Molecular cloning of the cDNA and chromosome localization of the gene for human ubiquitin-conjugating enzyme 9. J. Biol. Chem. 271 (1996) 24811-24816
8. Watanabe T.K., Fujiwara T., Kawai A., Shimizu F., Takami S., Hirano H., Okuno S., Ozaki K., Takeda S., Shimada Y., Nagata M., Takaichi A., Takahashi E., Nakamura Y., and Shin S. Cloning, expression, and mapping of UBE2I, a novel gene encoding a human homologue of yeast ubiquitin-conjugating enzymes which are critical for regulating the cell cycle. Cytogenet. Cell Genet. 72 (1996) 86-89
9. Giorgino F., de Robertis O., Laviola L., Montrone C., Perrini S., McCowen K.C., and Smith R.J. The sentrin-conjugating enzyme mUbc9 interacts with GLUT4 and GLUT1 glucose transporters and regulates transporter levels in skeletal muscle cells. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 1125-1130
10. Mo Y.Y., Yu Y., Shen Z., and Beck W.T. Nucleolar delocalization of human topoisomerase I in response to topotecan correlates with sumoylation of the protein. J. Biol. Chem. 277 (2002) 2958-2964
11. al-Khodairy F., Enoch T., Hagan I.M., and Carr A.M. The Schizosaccharomyces pombe hus5 gene encodes a ubiquitin conjugating enzyme required for normal mitosis. J. Cell Sci. 108 Pt. 2 (1995) 475-486
12. Seufert W., Futcher B., and Jentsch S. Role of a ubiquitin-conjugating enzyme in degradation of S- and M-phase cyclins. Nature 373 (1995) 78-81
13. Mo Y.Y., Yu Y., Ee P.L., and Beck W.T. Overexpression of a dominant-negative mutant Ubc9 is associated with increased sensitivity to anticancer drugs. Cancer Res. 64 (2004) 2793-2798
14. Mo Y.Y., Yu Y., Theodosiou E., Rachel Ee P.L., and Beck W.T. A role for Ubc9 in tumorigenesis. Oncogene 24 (2005) 2677-2683
15. Jacquiau H.R., van Waardenburg R.C., Reid R.J., Woo M.H., Guo H., Johnson E.S., and Bjornsti M.A. Defects in SUMO (small ubiquitin-related modifier) conjugation and deconjugation alter cell sensitivity to DNA topoisomerase I-induced DNA damage. J. Biol. Chem. 280 (2005) 23566-23575
16. Mo Y.Y., and Beck W.T. Association of human DNA topoisomerase IIalpha with mitotic chromosomes in mammalian cells is independent of its catalytic activity. Exp. Cell Res. 252 (1999) 50-62
17. Chauchereau A., Amazit L., Quesne M., Guiochon-Mantel A., and Milgrom E. Sumoylation of the progesterone receptor and of the steroid receptor coactivator SRC-1. J. Biol. Chem. 278 (2003) 12335-12343
18. Brummelkamp T.R., Bernards R., and Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science 296 (2002) 550-553
19. Verger A., Perdomo J., and Crossley M. Modification with SUMO. A role in transcriptional regulation. EMBO Rep. 4 (2003) 137-142
20. Lin C.Y., Strom A., Vega V.B., Kong S.L., Yeo A.L., Thomsen J.S., Chan W.C., Doray B., Bangarusamy D.K., Ramasamy A., Vergara L.A., Tang S., Chong A., Bajic V.B., Miller L.D., Gustafsson J.A., and Liu E.T. Discovery of estrogen receptor alpha target genes and response elements in breast tumor cells. Genome Biol. 5 (2004) R66
21. Bouras T., Southey M.C., Chang A.C., Reddel R.R., Willhite D., Glynne R., Henderson M.A., Armes J.E., and Venter D.J. Stanniocalcin 2 is an estrogen-responsive gene coexpressed with the estrogen receptor in human breast cancer. Cancer Res. 62 (2002) 1289-1295
22. Brown A.M., Jeltsch J.M., Roberts M., and Chambon P. Activation of pS2 gene transcription is a primary response to estrogen in the human breast cancer cell line MCF-7. Proc. Natl. Acad. Sci. U. S. A. 81 (1984) 6344-6348
23. Sheikh M.S., Shao Z.M., Hussain A., Chen J.C., Roberts Jr. C.T., LeRoith D., and Fontana J.A. Retinoic acid and estrogen modulation of insulin-like growth factor binding protein-4 gene expression and the estrogen receptor status of human breast carcinoma cells. Biochem. Biophys. Res. Commun. 193 (1993) 1232-1238
24. Pentecost B.T., Bradley L.M., Gierthy J.F., Ding Y., and Fasco M.J. Gene regulation in an MCF-7 cell line that naturally expresses an estrogen receptor unable to directly bind DNA. Mol. Cell Endocrinol. 238 (2005) 9-25
25. Leek R.D., Kaklamanis L., Pezzella F., Gatter K.C., and Harris A.L. bcl-2 in normal human breast and carcinoma, association with oestrogen receptor-positive, epidermal growth factor receptor-negative tumours and in situ cancer. Br. J. Cancer 69 (1994) 135-139
26. Contreras B., and Talamantes F. Growth hormone (GH) and 17beta-estradiol regulation of the expression of mouse GH receptor and GH-binding protein in cultured mouse hepatocytes. Endocrinology 140 (1999) 4725-4731
27. Kuang W.W., Thompson D.A., Hoch R.V., and Weigel R.J. Differential screening and suppression subtractive hybridization identified genes differentially expressed in an estrogen receptor-positive breast carcinoma cell line. Nucleic Acids Res. 26 (1998) 1116-1123
28. Hyder S.M., Nawaz Z., Chiappetta C., and Stancel G.M. Identification of functional estrogen response elements in the gene coding for the potent angiogenic factor vascular endothelial growth factor. Cancer Res. 60 (2000) 3183-3190
29. Ambrosino C., Cicatiello L., Cobellis G., Addeo R., Sica V., Bresciani F., and Weisz A. Functional antagonism between the estrogen receptor and Fos in the regulation of c-fos protooncogene transcription. Mol. Endocrinol. 7 (1993) 1472-1483
30. Teixeira C., Reed J.C., and Pratt M.A. Estrogen promotes chemotherapeutic drug resistance by a mechanism involving Bcl-2 proto-oncogene expression in human breast cancer cells. Cancer Res. 55 (1995) 3902-3907
31. Zhang G.J., Kimijima I., Tsuchiya A., and Abe R. The role of bcl-2 expression in breast carcinomas (review). Oncol. Rep. 5 (1998) 1211-1216
32. Martinez-Arribas F., Nunez-Villar M.J., Lucas A.R., Sanchez J., Tejerina A., and Schneider J. Immunofluorometric study of Bcl-2 and Bax expression in clinical fresh tumor samples from breast cancer patients. Anticancer Res. 23 (2003) 565-568
33. Alderson L.M., Castleberg R.L., Harsh G.R.t., Louis D.N., and Henson J.W. Human gliomas with wild-type p53 express bcl-2. Cancer Res. 55 (1995) 999-1001
34. Catz S.D., and Johnson J.L. BCL-2 in prostate cancer: a minireview. Apoptosis 8 (2003) 29-37
35. Cory S., Huang D.C., and Adams J.M. The Bcl-2 family: roles in cell survival and oncogenesis. Oncogene 22 (2003) 8590-8607
36. Wilson B.E., Mochon E., and Boxer L.M. Induction of bcl-2 expression by phosphorylated CREB proteins during B-cell activation and rescue from apoptosis. Mol. Cell Biol. 16 (1996) 5546-5556
37. Chen S.J., Li H., Durand J., Oparil S., and Chen Y.F. Estrogen reduces myointimal proliferation after balloon injury of rat carotid artery. Circulation 93 (1996) 577-584
38. Sentis S., Le Romancer M., Bianchin C., Rostan M.C., and Corbo L. SUMOylation of the Estrogen receptor {alpha} hinge region by SUMO-E3 ligases PIAS1 and PIAS3 regulates ER{alpha} transcriptional activity. Mol. Endocrinol. (2005)
39. Pearce S.T., and Jordan V.C. The biological role of estrogen receptors alpha and beta in cancer. Crit. Rev. Oncol. Hematol. 50 (2004) 3-22
40. Tremblay A., Tremblay G.B., Labrie F., and Giguere V. Ligand-independent recruitment of SRC-1 to estrogen receptor beta through phosphorylation of activation function AF-1. Mol. Cell 3 (1999) 513-519
41. Lipkowitz S. The role of the ubiquitination-proteasome pathway in breast cancer: ubiquitin mediated degradation of growth factor receptors in the pathogenesis and treatment of cancer. Breast Cancer Res. 5 (2003) 8-15
42. Gill G. Post-translational modification by the small ubiquitin-related modifier SUMO has big effects on transcription factor activity. Curr. Opin. Genet. Dev. 13 (2003) 108-113
43. Kirkin V., Joos S., and Zornig M. The role of Bcl-2 family members in tumorigenesis. Biochim. Biophys. Acta 1644 (2004) 229-249
44. Kotaja N., Karvonen U., Janne O.A., and Palvimo J.J. The nuclear receptor interaction domain of GRIP1 is modulated by covalent attachment of SUMO-1. J. Biol. Chem. 277 (2002) 30283-30288
45. Poukka H., Aarnisalo P., Karvonen U., Palvimo J.J., and Janne O.A. Ubc9 interacts with the androgen receptor and activates receptor-dependent transcription. J. Biol. Chem. 274 (1999) 19441-19446
46. Poukka H., Karvonen U., Janne O.A., and Palvimo J.J. Covalent modification of the androgen receptor by small ubiquitin-like modifier 1 (SUMO-1). Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 14145-14150
47. Le Drean Y., Mincheneau N., Le Goff P., and Michel D. Potentiation of glucocorticoid receptor transcriptional activity by sumoylation. Endocrinology 143 (2002) 3482-3489
48. Leo C., and Chen J.D. The SRC family of nuclear receptor coactivators. Gene 245 (2000) 1-11
49. Dechering K., Boersma C., and Mosselman S. Estrogen receptors alpha and beta: two receptors of a kind?. Curr. Med. Chem. 7 (2000) 561-576
50. Sun M., Paciga J.E., Feldman R.I., Yuan Z., Coppola D., Lu Y.Y., Shelley S.A., Nicosia S.V., and Cheng J.Q. Phosphatidylinositol-3-OH Kinase (PI3K)/AKT2, activated in breast cancer, regulates and is induced by estrogen receptor alpha (ERalpha) via interaction between ERalpha and PI3K. Cancer Res. 61 (2001) 5985-5991
51. Kaul S., Blackford Jr. J.A., Cho S., and Simons Jr. S.S. Ubc9 is a novel modulator of the induction properties of glucocorticoid receptors. J. Biol. Chem. 277 (2002) 12541-12549
52. Kurtzman A.L., and Schechter N. Ubc9 interacts with a nuclear localization signal and mediates nuclear localization of the paired-like homeobox protein Vsx-1 independent of SUMO-1 modification. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 5602-5607